Opioid-Induced Constipation Treatment Market: By Drug Type (Peripherally restricted ?-opioid receptor antagonists, Non-selective opioid antagonists, ? -opioid receptor antagonists, Locally acting chloride channel activators), By Formulation Type (Solids, Semi-solids, Liquids), By Administration (Oral, Parenteral), By Distribution Channel (Drugstore, Retail pharmacies, Hospital pharmacies) and Geography  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Opioid Induced Constipation Treatment Market size is valued at USD 2911.97 million in 2022 and is poised to grow at a CAGR of  4.7% from 2023-2029. Global Opioid Induced Constipation Treatment Market are the drugs used for its pain relieving properties in non-cancer and chronic kidney diease (ckd) drugs pain. The adverse effects associated with the opioids are decreasing gastrointestinal tracts motility, making patients strain, and making of solid discharges. Furthermore, long-term use of opioids cause harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard tools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite. The Opioid-Induced Constipation Treatment Marketgrowing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global Opioid-Induced Constipation Treatment Market. Furthermore, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the Opioid-Induced Constipation Treatment Market over the forecast period. However, lack of awareness regarding opioid induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the opioid-induced constipation treatment market. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Opioid Induced Constipation Treatment Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Opioid Induced Constipation Treatment Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Global Opioid Induced Constipation Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

4.7%

Largest Market

North-America

Fastest Growing Market

Europe
Opioid Induced Constipation Treatment Market Dynamics

Opioid-induced constipation is becoming increasingly common. In 2013, the American Academy of Pain Medicine (AAPM) estimated that about 100 million individuals in the United States experienced opioid-induced constipation. Furthermore, the AAPM predicted that the number of instances would increase as the number of people using opioids increased. There is a rising awareness of the availability of a wide range of opioid medications. Patients will be more likely to use these medications to treat chronic pain as a result of this. The growing number of people suffering from opioid-induced constipation, particularly in North America, is expected to propel the total opioid-induced constipation treatment business forward. Because of the enormous number of persons who take opioid medicines, the regional market is expected to increase at a significant rate. This is due to the high prevalence of chronic pain-related diseases in this area.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Opioid Induced Constipation Treatment Market Segmentation

By Drug Type
  • Peripherally restricted ?-opioid receptor antagonists
  • Non-selective opioid antagonists
  • ? -opioid receptor antagonists
  • Locally acting chloride channel activators
By Formulation Type
  • Solids
  • Semi-solids
  • Liquids
Distribution Channel
  • Drugstore
  • Retail pharmacies
  • Hospital pharmacies

Frequently Asked Questions

The opioid-induced constipation treatment market size was valued at USD 2911.97 million in 2022

Rise in the Availability of Effective OIC Drugs Along with Growing Prevalence of Chronic Idiopathic Pains

Europe is the fastest-growing for opioid-induced constipation treatment market

1. Executive summary

2. Global Opioid-Induced Constipation Treatment Market Introduction

   2.1. Global Opioid-Induced Constipation Treatment Market Taxonomy

   2.2. Global Opioid-Induced Constipation Treatment Market Definitions

     2.2.1. Type of vaccine

    2.2.2. End User

3. Global Opioid-Induced Constipation Treatment Market Dynamics

   3.1. Drivers

   3.2. Restraints

   3.3. Opportunities/Unmet Needs of the Market

   3.4. Trends

   3.5. Global Opioid-Induced Constipation Treatment Market Dynamics Factors Impact Analysis

   3.6. Global Opioid-Induced Constipation Treatment Market Regulations

      3.6.1. U.S 

      3.6.2. Europe

      3.6.3. Japan

      3.6.4. China

3.7. Global Opioid-Induced Constipation Treatment Market Product Innovations

4. Global Opioid-Induced Constipation Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

  4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

  4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

 4.3. Market Oppurtunity Analysis

5. Global Opioid-Induced Constipation Treatment Market, By Drug Type, 2018 - 2022 and Forecast, 2023 - 2029

  5.1. Peripherally restricted ?-opioid receptor antagonists

    5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

    5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

    5.1.3. Market Opportunity Analysis

 5.2. Non-selective opioid antagonists

     5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

     5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

    5.2.3. Market Opportunity Analysis

5.3. ? -opioid receptor antagonists

   5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

    5.3.3. Market Opportunity Analysis

6. Global Opioid-Induced Constipation Treatment Market Forecast, By Formulation Type, 2018 - 2022 and Forecast, 2023 - 2029

    6.1. Solids

     6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

     6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

    6.1.3. Market Opportunity Analysis

6.2. Semi-Solids 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

   6.2.3. Market Opportunity Analysis

 6.3. Liquids 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

   6.3.3. Market Opportunity Analysis

7. Global Opioid-Induced Constipation Treatment Market Forecast, By Route of administration , 2018 - 2022 and Forecast, 2023 - 2029

  7.1. Oral 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

    7.1.3. Market Opportunity Analysis

 7.2. Parenteral

    7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 

 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 7.2.3. Market Opportunity Analysis

8. Global Opioid-Induced Constipation Treatment Market Forecast, By Distribution Channel , 2018 - 2022 and Forecast, 2023 - 2029

 8.1. Drug Stores

   8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

   8.1.3. Market Opportunity Analysis 8.2. Retail Pharmacies

   8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

   8.2.3. Market Opportunity Analysis

  8.3. Hospital Pharmacies

     8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

     8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

     8.3.3. Market Opportunity Analysis

9. Global Opioid-Induced Constipation Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029

  9.1. North America

    9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 

    9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

    9.1.3. Market Opportunity Analysis

9.2. Europe

   9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

   9.2.3. Market Opportunity Analysis

 9.3. Asia-Pacific

   9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

   9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

   9.3.3. Market Opportunity Analysis

9.4. Latin America 

    9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

    9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

    9.4.3. Market Opportunity Analysis 9.5. Middle East and Africa

 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

9.5.3. Market Opportunity Analysis

9.6. Global Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2023 - 2029

10. North America Opioid-Induced Constipation Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

  10.1.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

    10.1.1.1. Peripherally restricted ?-opioid receptor antagonists

    10.1.1.2. Non-selective opioid antagonists

    10.1.1.3. ? -opioid receptor antagonists

    10.1.1.4. Locally acting chloride channel activators

 10.1.2. Formulation Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

   10.1.2.1. Solids

   10.1.2.2. Semi-Solids

   10.1.2.3. Liquids

10.1.3. Route of administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

   10.1.3.1. Oral

   10.1.3.2. Parenteral

   10.1.4. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

   10.1.4.1. Drugstore

10.1.4.2. Retail pharmacies

10.1.4.3. Hospital pharmacies

10.1.5. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

   10.1.5.1. U.S.

   10.1.5.2. Canada

10.1.6. North America Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029

10.1.7. North America Opioid-Induced Constipation Treatment Market Dynamics Trends

11. Europe Opioid-Induced Constipation Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

   11.1.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

   11.1.1.1. Peripherally restricted ?-opioid receptor antagonists

   11.1.1.2. Non-selective opioid antagonists

   11.1.1.3. ? -opioid receptor antagonists 

   11.1.1.4. Locally acting chloride channel activators

 11.1.2. Formulation Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

   11.1.2.1. Solids 11.1.2.2. Semi-Solids

   11.1.2.3. Liquids

 11.1.3. Route of administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

   11.1.3.1. Oral

   11.1.3.2. Parenteral

11.1.4. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

  11.1.4.1. Drugstore

  11.1.4.2. Retail pharmacies

  11.1.4.3. Hospital pharmacies

11.1.5. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

   11.1.5.1. Germany

  11.1.5.2. UK

  11.1.5.3. France

  11.1.5.4. Spain

  11.1.5.5. Italy

  11.1.5.6. Russia

  11.1.5.7. Poland

  11.1.5.8. Rest of Europe

  11.1.6. Europe Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029

  11.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics Trends

12. Asia-Pacific Opioid-Induced Constipation Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

   12.1.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

   12.1.1.1. Peripherally restricted ?-opioid receptor antagonists

   12.1.1.2. Non-selective opioid antagonists

   12.1.1.3. ? -opioid receptor antagonists

   12.1.1.4. Locally acting chloride channel activators

      12.1.2. Formulation Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 

      12.1.2.1. Solids

 12.1.2.2. Semi-Solids

  12.1.2.3. Liquids

  12.1.3. Route of administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

  12.1.3.1. Oral

  12.1.3.2. Parenteral

12.1.4. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

    12.1.4.1. Drugstore

    12.1.4.2. Retail pharmacies

   12.1.4.3. Hospital pharmacies 

  12.1.5. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

  12.1.5.1. Japan

  12.1.5.2. China

  12.1.5.3. India

   12.1.5.4. ASEAN

   12.1.5.5. Australia & New Zealand

  12.1.5.6. Rest of Asia-Pacific

  12.1.6. Asia-Pacific Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029 12.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics Trends

13. Latin America Opioid-Induced Constipation Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

  13.1.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

   13.1.1.1. Peripherally restricted ?-opioid receptor antagonists

   13.1.1.2. Non-selective opioid antagonists

   13.1.1.3. ? -opioid receptor antagonists

  13.1.1.4. Locally acting chloride channel activators

13.1.2. Formulation Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

  13.1.2.1. Solids

  13.1.2.2. Semi-Solids

  13.1.2.3. Liquids

  13.1.3. Route of administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

  13.1.3.1. Oral

  13.1.3.2. Parenteral 

 13.1.4. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 

    13.1.4.1. Drugstore 

    13.1.4.2. Retail pharmacies

    13.1.4.3. Hospital pharmacies

  13.1.5. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

    13.1.5.1. Brazil

     13.1.5.2. Mexico

     13.1.5.3. Argentina

     13.1.5.4. Venezuela

     13.1.5.5. Rest of Latin America 

    13.1.6. Latin America Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029

13.1.7. Latin America Opioid-Induced Constipation Treatment Market Dynamics Trends

14. Middle East and Africa Opioid-Induced Constipation Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

   14.1.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

   14.1.1.1. Peripherally restricted ?-opioid receptor antagonists

   14.1.1.2. Non-selective opioid antagonists

  14.1.1.3. ? -opioid receptor antagonists

  14.1.1.4. Locally acting chloride channel activators 

  14.1.2. Formulation Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

  14.1.2.1. Solids

   14.1.2.2. Semi-Solids

   14.1.2.3. Liquids

  14.1.3. Route of administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

     14.1.3.1. Oral

     14.1.3.2. Parenteral

14.1.4. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

    14.1.4.1. Drugstore

     14.1.4.2. Retail pharmacies

     14.1.4.3. Hospital pharmacies 

    14.1.5. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

     14.1.5.1. Gulf Cooperation Council (GCC) Countries

     14.1.5.2. Israel

     14.1.5.3. South Africa

     14.1.5.4. Rest of MEA

  14.1.6. MEA Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029 

14.1.7. MEA Opioid-Induced Constipation Treatment Market Dynamics Trends

15. Competition Landscape

 15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) 1

    5.2.1. GlaxoSmithKline plc (U.K.)

    15.2.2. AstraZeneca U.K) 

    15.2.3. Pfizer Inc. (U.S.)

    15.2.4. SLA Pharma AG (U.K.)

    15.2.5. AIKO Biotechnology, Inc. (U.S.)

    15.2.6. Cubist Pharmaceuticals (Merck & Co. Inc.,) (U.S.)

   15.2.7. Takeda Pharmaceutical Company Limited (Japan)

   15.2.8. Boehringer Ingelheim GmbH (Germany)

   15.2.9. Bayer AG (Germany)

   15.2.10. Valeant (Canada)

   15.2.11. Abbott Laboratories (U.S.)

    15.2.12. Purdue Pharma LP (U.S.)

     15.2.13. Shionogi Inc. (U.S.)

      15.2.14. Cosmo Pharmaceuticals N.V. (Ireland)

16. Research Methodology

17. Key Assumptions and Acronyms

  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca U.K)
  • Pfizer Inc. (U.S.)
  • SLA Pharma AG (U.K.)
  • AIKO Biotechnology, Inc. (U.S.)
  • Cubist Pharmaceuticals (Merck & Co. Inc.,) (U.S.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Boehringer Ingelheim GmbH (Germany)
  • Bayer AG (Germany)
  • Valeant (Canada)
  • Abbott Laboratories (U.S.)
  • Purdue Pharma LP (U.S.)
  • Shionogi Inc. (U.S.)
  • Cosmo Pharmaceuticals  N.V. (Ireland)